Drug
Bivatuzumab mertansine clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How studies write it
Studies that test it under each name
Name
- bivatuzumab mertansine
- 4
Studies by the year they started
4 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Immunotoxins source
Studies
Open first, then newest update. How each study uses bivatuzumab mertansine is read from its arms, and is right about nine times in ten.
Testing it · 4
- Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1Boehringer IngelheimNCT02254018Written as bivatuzumab mertansine
- Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast CancerCompletedPhase 1Boehringer IngelheimNCT02254005Written as bivatuzumab mertansine
- Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast CancerTerminatedPhase 1Boehringer IngelheimNCT02254031Written as bivatuzumab mertansine
- Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or EsophagusTerminatedPhase 1Boehringer IngelheimNCT02254044Written as bivatuzumab mertansine
Codes
What other systems call bivatuzumab mertansine · ClinicalTrials.gg INT005074
- MeSH (NLM) C519271bivatuzumab mertansineOne source ClinicalTrials.gov
- UNII (FDA) 074GT4PR9DBIVATUZUMAB MERTANSINEOne source FDA
- NCI Thesaurus C216392Bivatuzumab MertansineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C519271 | bivatuzumab mertansine | One source ClinicalTrials.gov |
| UNII (FDA) | 074GT4PR9D | BIVATUZUMAB MERTANSINE | One source FDA |
| NCI Thesaurus | C216392 | Bivatuzumab Mertansine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.